Is This A Contrarian Buy Signal For GlaxoSmithKline plc?

Underperformance and generic competition are short-term issues, and may be masking a long-term opportunity for shareholders in GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It’s been a disappointing 12 months for shareholders of GlaxoSmithKline (LSE: GSK).

A planned £4bn capital return has been slashed to just £1bn, and the pharma giant’s share price has lagged those of its peer group quite badly:

Company

12-month share price movt.

GlaxoSmithKline

-9%

AstraZeneca

-3%

Shire

+11%

Pfizer

+15%

Novartis

+23%

Amgen

+35%

Eli Lilly

+36%

Glaxo has also underperformed the FTSE 100 over the last five years, climbing 14% versus 26% for the blue-chip index.

However, every cloud has a silver lining. In Glaxo’s case, I believe that the firm’s underperformance could be a strong buying opportunity.

A long game

Glaxo’s current woes are due to a shortage of major products to replace the falling revenues from products such as respiratory drug Advair, which have lost patent protection.

First-quarter core earnings per share were down by 16% on a constant exchange rate basis, and Glaxo’s full-year outlook is for a decline “in the high teens”. Over the last year, cash flow has weakened and exchange rate factors have worked against the firm.

The firm’s complex cash and asset-swap transaction with Novartis should have resulted in a £4bn (80p per share) cash return to shareholders. In May, this was reduced to £1bn (20p per share) in order to protect Glaxo’s credit ratings and improve its financial flexibility. None of this has helped Glaxo’s share price, but the company expects to report significant growth from 2016 onwards, and I believe that investors need to share this longer view.

Developing major new pharmaceutical products isn’t fast or predictable, but it can result in big wins. Take this week’s news that US firm Eli Lilly has an experimental product, solanezumab, that could be a major breakthrough in the treatment of Alzheimer’s.

Some estimates suggest that if further trials are successful, this product could generate sales of $11bn per year. Alternatively, it may join the long list of failed Alzheimer’s treatments. There’s no way of knowing, which is why major firms like Glaxo and Eli Lilly always have many more products under development than they expect to commercialise.

Backed by top investors

I’m confident that Glaxo’s pipeline of new products will deliver some successes over the next few years. I also believe the potential of firm’s existing assets, such as the ViiV Healthcare HIV business and Glaxo’s vaccines division, is not currently reflected in Glaxo’s share price.

That’s a view shared by top UK fund manager Neil Woodford. The view of Mr Woodford’s fund, which has added to its Glaxo holding in recent months, is that Glaxo’s individual divisions are collectively worth “significantly” more than Glaxo’s current market value.

Not expensive

The final point to note is that Glaxo does not look expensive at today’s valuation. The firm’s shares trade on a 2016 forecast P/E of 15.5 and on about 13 times average earnings per share from the last five years.

This year’s £1bn cash return means that the shares offer a prospective yield of 7.4% for 2015, falling to 5.9% for 2016 and 2017, when Glaxo is planning to pay a dividend of 80p per share.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »